Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors - CA234-0001
Mis à jour: 2 avril, 2025 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Site(s)
Recruiting
Inclusion Criteria: - Participant must be ≥ 18 years of age. - Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:. - Part 1A: clear-cell renal cell carcinoma (ccRCC) or clear-cell ovarian cancer (ccOC). - Parts 2A, 1D, 2D: ccRCC. i) Part 1B: solid tumors with KRAS G12C mutation. ii) Part 2B: NSCLC with KRAS G12C mutation. iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation. - Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1. - Participants must have measurable disease per RECIST v1.1. Exclusion Criteria: - Untreated central nervous system (CNS) metastases. - Leptomeningeal metastasis (carcinomatous meningitis). - Impaired cardiac function or clinically significant cardiac disease. - For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):. i) History of pneumonitis or interstitial lung disease (ILD). ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). - Other protocol-defined inclusion/exclusion criteria apply.
Nous vous recommandons vivement de contacter BMS pour signaler les effets secondaires (événements indésirables)
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici
Signaler des plaintes concernant des effets indésirables (effets indésirables) ou des produits: Informations médicales
